PortfoliosLab logoPortfoliosLab logo
NUVB vs. AMPX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NUVB vs. AMPX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nuvation Bio Inc. (NUVB) and Amprius Technologies Inc. (AMPX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NUVB achieves a -42.30% return, which is significantly lower than AMPX's 185.68% return.


NUVB

1D
9.53%
1M
7.04%
YTD
-42.30%
6M
-37.79%
1Y
111.02%
3Y*
45.17%
5Y*
-15.85%
10Y*

AMPX

1D
3.68%
1M
5.33%
YTD
185.68%
6M
84.45%
1Y
722.63%
3Y*
39.80%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

NUVB vs. AMPX - Yearly Performance Comparison


2026 (YTD)2025202420232022
NUVB
Nuvation Bio Inc.
-42.30%236.84%76.16%-21.35%-18.30%
AMPX
Amprius Technologies Inc.
185.68%181.79%-47.07%-33.29%-20.70%

Correlation

The correlation between NUVB and AMPX is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Sep 16, 2022

0.19

Fundamentals

Market Cap

NUVB:

$1.95B

AMPX:

$3.09B

EPS

NUVB:

-$0.42

AMPX:

-$0.31

PS Ratio

NUVB:

12.69

AMPX:

32.30

PB Ratio

NUVB:

6.11

AMPX:

28.21

Total Revenue (TTM)

NUVB:

$143.05M

AMPX:

$90.26M

Gross Profit (TTM)

NUVB:

$131.08M

AMPX:

$16.37M

EBITDA (TTM)

NUVB:

-$139.03M

AMPX:

-$17.72M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NUVB vs. AMPX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUVB
NUVB Risk / Return Rank: 7575
Overall Rank
NUVB Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
NUVB Sortino Ratio Rank: 7777
Sortino Ratio Rank
NUVB Omega Ratio Rank: 7979
Omega Ratio Rank
NUVB Calmar Ratio Rank: 7474
Calmar Ratio Rank
NUVB Martin Ratio Rank: 6969
Martin Ratio Rank

AMPX
AMPX Risk / Return Rank: 9797
Overall Rank
AMPX Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
AMPX Sortino Ratio Rank: 9595
Sortino Ratio Rank
AMPX Omega Ratio Rank: 9292
Omega Ratio Rank
AMPX Calmar Ratio Rank: 9999
Calmar Ratio Rank
AMPX Martin Ratio Rank: 9898
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NUVB vs. AMPX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nuvation Bio Inc. (NUVB) and Amprius Technologies Inc. (AMPX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NUVBAMPXDifference
Sharpe ratioReturn per unit of total volatility

-5.51

Sortino ratioReturn per unit of downside risk

-1.94

Omega ratioGain probability vs. loss probability

1.29

1.49

-0.20

Calmar ratioReturn relative to maximum drawdown

1.94

15.72

-13.78

Martin ratioReturn relative to average drawdown

3.54

38.65

-35.11

NUVB vs. AMPX - Sharpe Ratio Comparison

The current NUVB Sharpe Ratio is 1.22, which is lower than the AMPX Sharpe Ratio of 6.73. The chart below compares the historical Sharpe Ratios of NUVB and AMPX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NUVBAMPXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.22

6.73

-5.51

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.21

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.15

0.19

-0.34

Drawdowns

NUVB vs. AMPX - Drawdown Comparison

The maximum NUVB drawdown since its inception was -93.39%, roughly equal to the maximum AMPX drawdown of -94.49%. Use the drawdown chart below to compare losses from any high point for NUVB and AMPX.


Loading charts...

Drawdown Indicators


NUVBAMPXDifference

Max Drawdown

Largest peak-to-trough decline

-93.39%

-94.49%

+1.10%

Max Drawdown (1Y)

Largest decline over 1 year

-57.55%

-46.41%

-11.14%

Max Drawdown (3Y)

Largest decline over 3 years

-58.19%

-93.11%

+34.92%

Max Drawdown (5Y)

Largest decline over 5 years

-92.88%

Current Drawdown

Current decline from peak

-64.52%

-1.62%

-62.90%

Average Drawdown

Average peak-to-trough decline

-65.50%

-55.21%

-10.29%

Ulcer Index

Depth and duration of drawdowns from previous peaks

31.46%

18.84%

+12.62%

Volatility

NUVB vs. AMPX - Volatility Comparison

The current volatility for Nuvation Bio Inc. (NUVB) is 18.34%, while Amprius Technologies Inc. (AMPX) has a volatility of 44.87%. This indicates that NUVB experiences smaller price fluctuations and is considered to be less risky than AMPX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NUVBAMPXDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.34%

44.87%

-26.53%

Volatility (6M)

Calculated over the trailing 6-month period

53.53%

78.30%

-24.77%

Volatility (1Y)

Calculated over the trailing 1-year period

91.74%

108.51%

-16.77%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

75.58%

128.77%

-53.19%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

73.11%

128.77%

-55.66%

Dividends

NUVB vs. AMPX - Dividend Comparison

Neither NUVB nor AMPX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NUVB vs. AMPX - Financials Comparison

This section allows you to compare key financial metrics between Nuvation Bio Inc. and Amprius Technologies Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M20222023202420252026
83.23M
28.54M
(NUVB) Total Revenue
(AMPX) Total Revenue
Values in USD except per share items

NUVB vs. AMPX - Profitability Comparison

The chart below illustrates the profitability comparison between Nuvation Bio Inc. and Amprius Technologies Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-100.0%-50.0%0.0%50.0%100.0%20222023202420252026
93.3%
20.1%
Portfolio components
NUVB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Nuvation Bio Inc. reported a gross profit of 77.61M and revenue of 83.23M. Therefore, the gross margin over that period was 93.3%.

AMPX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Amprius Technologies Inc. reported a gross profit of 5.74M and revenue of 28.54M. Therefore, the gross margin over that period was 20.1%.

NUVB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Nuvation Bio Inc. reported an operating income of 3.88M and revenue of 83.23M, resulting in an operating margin of 4.7%.

AMPX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Amprius Technologies Inc. reported an operating income of -6.69M and revenue of 28.54M, resulting in an operating margin of -23.4%.

NUVB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Nuvation Bio Inc. reported a net income of 5.40M and revenue of 83.23M, resulting in a net margin of 6.5%.

AMPX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Amprius Technologies Inc. reported a net income of -5.05M and revenue of 28.54M, resulting in a net margin of -17.7%.


Frequently Asked Questions


NUVB and AMPX have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AMPX has higher volatility (44.87%) compared to NUVB (18.34%). In terms of maximum drawdown, NUVB dropped -93.39% vs AMPX's -94.49%.

AMPX currently has the higher Sharpe Ratio (6.73 vs 1.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NUVB and AMPX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer